Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico

Background. Although chemotherapy added to rituximab is a standard of care for diffuse large B cell lymphoma (DLBCL), treatment of patients ≥65 years of age remains controversial due to comorbidities. Methods. This is a retrospective, comparative, nonrandomized study of patients ≥65 years of age, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolasco-Medina, Diana, Reynoso-Noveron, Nancy, Mohar-Betancourt, Alejandro, Aviles-Salas, Alejandro, García-Perez, Osvaldo, Candelaria, Myrna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958419/
https://www.ncbi.nlm.nih.gov/pubmed/27478844
http://dx.doi.org/10.1155/2016/9817606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958419/
https://www.ncbi.nlm.nih.gov/pubmed/27478844
http://dx.doi.org/10.1155/2016/9817606

Ejemplares similares